Cadonilimab, a PD-1/CTLA-4 bispecific antibody in unresectable hepatocellular carcinoma: a real-world study

Cadonilimab, a PD-1/CTLA-4 bispecific antibody in unresectable hepatocellular carcinoma: a real-world study

Abstract Objective This study retrospectively evaluated the safety and efficacy of cadonilimab combined with tyrosine kinase inhibitors (TKI) for the treatment of unresectable hepatocellular carcinoma (uHCC). Patients and methods Seventy-eight patients who received cadonilimab + TKI were included; 4...

Full description

Saved in:
Bibliographic Details
Main Authors: Yilin Wang, Shida Pan, Jiahe Tian, Jianing Wang, Yingying Yu, Siyu Wang, Fengyi Li, Luo Yang, Xiaomeng Liu, Yingjuan Shen, Qin Qiu, Junqing Luan, Mengdie Jia, Chuyue Xiong, Xuanxuan Duan, Fu-Sheng Wang, Fanping Meng
Format: Article
Language:English
Published: Springer 2025-04-01
Series:Cancer Immunology, Immunotherapy
Subjects:
Unresectable hepatocellular carcinoma
Cadonilimab
Bispecific antibody
Real-world data
Online Access:https://doi.org/10.1007/s00262-025-04038-8
Tags: Add Tag
No Tags, Be the first to tag this record!

Internet

https://doi.org/10.1007/s00262-025-04038-8

Similar Items